Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • NextGenSeq
    Senior Member
    • Apr 2009
    • 482

    #1

    A Hammer Thrown at Big Brother?

    Oxford Nanopore Technologies, the company that pioneered a new DNA analysis technique called nanopore sequencing, has remained secretive about the microscopic channel at the heart of its products. But on the heels of a patent infringement lawsuit from sequencing behemoth Illumina, Inc., the company has revealed what will drive its newest devices—a bacterial pore that seems to circumvent Illumina’s challenge.
    ...
    A webcast presentation today for customers of the company will likely put many of those fears to rest. Oxford Nanopore’s Chief Technology Officer Clive Brown announced an upgrade to its devices—a new pore the company has been describing in presentations as R9. Brown revealed that R9 is CsgG, a membrane protein derived from Escherichia coli, but present in many bacterial species.



    http://www.sciencemag.org/news/2016/...new-technology
  • ymc
    Senior Member
    • Mar 2010
    • 496

    #2
    If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.

    However, judging from ONT's past record, this might well be achievable but the timeline is more likely to be one or two years in the future. As a result, this lawsuit can still be a distraction for ONT for the time being IMHO.
    Attached Files

    Comment

    • luc
      Senior Member
      • Dec 2010
      • 469

      #3
      Originally posted by ymc View Post
      If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.
      I believe the track record of ONP/Clive Brown announcements is pretty abysmal.

      Comment

      • ymc
        Senior Member
        • Mar 2010
        • 496

        #4
        Originally posted by luc View Post
        I believe the track record of ONP/Clive Brown announcements is pretty abysmal.
        Yeah, so far they only delivered Minion and it was at least two years late.

        Comment

        • AllSeq
          Registered Vendor
          • Oct 2013
          • 138

          #5
          Originally posted by ymc View Post
          If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.
          Matching the error rate of PacBio would indeed be pretty impressive, but that alone is insufficient to kill off PacBio or Illumina. The question is does the ONT error profile match that of PacBio? In other words, is it stochastic and relatively free of GC bias so that at sufficient coverage the consensus error rate drops to very low levels (like PacBio). Or does it suffer from systematic errors that create a ceiling to the consensus read quality? Have these questions been definitely answered yet?
          AllSeq - The Sequencing Marketplace
          [email protected]
          www.AllSeq.com

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
            by SEQadmin2




            NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
            Today, 06:46 AM
          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-28-2026, 09:57 AM
          0 responses
          22 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-28-2026, 09:51 AM
          0 responses
          14 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          68 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          47 views
          0 reactions
          Last Post SEQadmin2  
          Working...